BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15877792)

  • 1. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B.
    Nikolaidis N; Vassiliadis T; Giouleme O; Tziomalos K; Grammatikos N; Patsiaoura K; Orfanou-Koumerkeridou E; Balaska A; Eugenidis N
    Clin Transplant; 2005 Jun; 19(3):321-6. PubMed ID: 15877792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.
    Sponseller CA; Bacon BR; Di Bisceglie AM
    Liver Transpl; 2000 Nov; 6(6):715-20. PubMed ID: 11084057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.
    Yao FY; Terrault NA; Freise C; Maslow L; Bass NM
    Hepatology; 2001 Aug; 34(2):411-6. PubMed ID: 11481627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long-term effects of lamivudine treatment in patients with HBeAg-negative liver cirrhosis.
    Kilic ZM; Kuran S; Akdogan M; Cicek B; Oguz D; Odemis B; Sasmaz N
    Adv Ther; 2008 Mar; 25(3):190-200. PubMed ID: 18385953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.
    Villeneuve JP; Condreay LD; Willems B; Pomier-Layrargues G; Fenyves D; Bilodeau M; Leduc R; Peltekian K; Wong F; Margulies M; Heathcote EJ
    Hepatology; 2000 Jan; 31(1):207-10. PubMed ID: 10613747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
    Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
    Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis.
    Bae SH; Yoon SK; Choi JY; Jang JW; Cho SH; Yang JM; Han NI; Ahn BM; Chung KW; Sun HS
    J Gastroenterol Hepatol; 2005 Oct; 20(10):1527-32. PubMed ID: 16174069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
    J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic efficacy of lamivudine in patients with hepatitis B virus-related decompensated cirrhosis in Korea].
    Jung S; Suh DJ; Park HJ; Park YH; Song HG; Lee HC; Chung YH; Lee YS
    Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):418-27. PubMed ID: 12506246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lamivudine treatment in patients with hepatitis B virus induced liver cirrhosis.
    Cetin K; Sabahattin K; Kadir D; Ahmet D; Ziyaettin D; Selim B; Mürüvvet B; Fatih B; Güngör B; Zeynel M; Yilmaz C; Atilla O
    Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccxcv-ccxcvii. PubMed ID: 15244206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features and survival in Chinese patients with hepatitis B e antigen-negative hepatitis B virus-related cirrhosis.
    Ma H; Wei L; Guo F; Zhu S; Sun Y; Wang H
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1250-8. PubMed ID: 18624896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.
    Manolakopoulos S; Bethanis S; Elefsiniotis J; Karatapanis S; Triantos C; Sourvinos G; Touloumi G; Economou M; Vlachogiannakos J; Spandidos D; Avgerinos A; Tzourmakliotis D
    Aliment Pharmacol Ther; 2006 Mar; 23(6):787-95. PubMed ID: 16556181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis.
    Tseng PL; Lu SN; Tung HD; Wang JH; Changchien CS; Lee CM
    J Viral Hepat; 2005 Jul; 12(4):386-92. PubMed ID: 15985009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The prospective study of the clinical features and outcome of HBeAg-negative and HBeAg-positive cirrhosis in patients with chronic type B hepatitis].
    Ma H; Guo F; Wei L; Sun Y; Wang H
    Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(26):1832-5. PubMed ID: 17922993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [One year and half treatment with lamivudine in active cirrhosis resulting from chronic hepatitis B].
    Zeng WQ; Guo SH; Zhang DZ; Zhou Z; Ren H; Zhang QH; Wang ZY
    Zhonghua Gan Zang Bing Za Zhi; 2003 Mar; 11(3):176-8. PubMed ID: 12681069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis.
    Ooga H; Suzuki F; Tsubota A; Arase Y; Suzuki Y; Akuta N; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Kumada H
    J Gastroenterol; 2004 Nov; 39(11):1078-84. PubMed ID: 15580401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study on efficacy of lamivudine therapy in decompensated cirrhosis of liver due to chronic hepatitis B virus infection.
    Sharma YR; Miah AR; Saha SK; Mohammed S; Rahman M; Roy PK; Hasan M
    Nepal Med Coll J; 2004 Dec; 6(2):106-11. PubMed ID: 16295739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension.
    Manolakopoulos S; Triantos C; Theodoropoulos J; Vlachogiannakos J; Kougioumtzan A; Papatheodoridis G; Tzourmakliotis D; Karamanolis D; Burroughs AK; Archimandritis A; Raptis S; Avgerinos A
    J Hepatol; 2009 Sep; 51(3):468-74. PubMed ID: 19616339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
    Zhu M; Xu B; Yao GB
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B.
    Fontana RJ; Keeffe EB; Carey W; Fried M; Reddy R; Kowdley KV; Soldevila-Pico C; McClure LA; Lok AS;
    Liver Transpl; 2002 May; 8(5):433-9. PubMed ID: 12004342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.